Transmedics (TMDX)

• Market cap: $3.12B
• 1 day: -0.45%
• 5 days: -0.53%
• 1 month: 36.76%
• 3 months: 37.43%
• 6 months: 12.32%
• Year to date: 38.36%
• 1 year: -2.25%
• 5 years: 408.62%
• 10 years: 311.49%
• Sector: Healthcare
• Industry: Medical Devices

About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Employees: 728

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

49% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 84

1.14% more ownership

Funds ownership: 108.63% [Q3] → 109.78% (+1.14%) [Q4]

16% less funds holding

Funds holding: 365 [Q3] → 308 (-57) [Q4]

17% less call options, than puts

Call options by funds: $51.6M | Put options by funds: $62.5M

40% less first-time investments, than exits

New positions opened: 73 | Existing positions closed: 122

59% less capital invested

Capital invested by funds: $5.67B [Q3] → $2.3B (-$3.37B) [Q4]

90% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 1 (-9) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $104 13% upside
• Avg. target: $105 14% upside
• High target: $105 14% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Matt O'Brien 46% 1-year accuracy 23 / 50 met price target	14% upside $105	Overweight Reiterated	29 Apr 2025
Canaccord Genuity William Plovanic 44% 1-year accuracy 21 / 48 met price target	13% upside $104	Buy Maintained	11 Mar 2025